Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year. EventsDates2025 annual revenueFebruary 5, 2026 (after market close)2025 annual resultsMarch 30, 2026 (before market opens)2026 Q1 revenueApril 29, 2026 (after market close)Annual General MeetingJune 25, 20262026 Half-year revenueJuly 30, 2026 (after market clos ...

Core Insights - WELL Health Technologies Corp. has announced the completion of a previously announced Series by its majority-owned subsidiary WELLSTAR Technologies Corp. [1] Company Overview - WELL Health Technologies Corp. is a digital healthcare company focused on improving health outcomes through technology [1] - The company aims to empower healthcare practitioners and their patients globally [1] Subsidiary Information - WELLSTAR Technologies Corp. is a majority-owned subsidiary of WELL Health Technologies Corp. [1] - The completion of the Series indicates progress in WELLSTAR's operational and financial strategies [1]

Core Insights - Sharecare has been selected as the exclusive advertising partner for CVIEW, enhancing its reach in the healthcare ecosystem [1] - This partnership aims to engage patients throughout their health journey, from prevention to ongoing care management [2] - The collaboration significantly expands Sharecare's point-of-care capabilities, now reaching over 2.5 million patients and caregivers monthly across more than 3,000 clinics [3] Company Overview - Sharecare is a digital healthcare company focused on improving care quality, driving better outcomes, and lowering costs through technology and data-driven insights [7] - The company provides a comprehensive platform that includes benefits navigation, care management, and health information management [7] Partnership Details - The CVIEW network allows life sciences brands to connect with over one million patients and caregivers each month in clinical settings [2] - This partnership is expected to create a powerful channel for health communication, bridging education and real-world impact [3] Performance Metrics - Sharecare's innovative solutions have shown audience quality that is two to three times better than data partners, with 73% of programs exceeding client benchmarks [4] - Engagement with Sharecare's programs increases the likelihood of patients discussing related health issues with their doctors by 63% [4]

Core Insights - WELL Health Technologies Corp. is experiencing strong momentum in its Canadian Patient Services business, driven by organic growth and improvements in clinic digitization [1] Group 1: Company Performance - The company is focused on leveraging technology to enhance health outcomes for healthcare practitioners and patients globally [1] - There have been meaningful improvements in clinic digitization, which is contributing to the overall growth of the business [1] Group 2: Business Strategy - The successful execution of the company's strategic plans is a key factor in its continued momentum [1]

Core Insights - Oscar Health's stock price increased from $13.82 to $23.80, representing a roughly 70% rise since August [1] Group 1: Stock Performance - The stock surged significantly following the publication of the previous article [1] - The increase in stock price highlights strong market interest and potential investor confidence in Oscar Health [1]

Core Insights - GoodRx Holdings, Inc. (NASDAQ:GDRX) has been identified as one of the best American penny stocks to buy, with Goldman Sachs raising its price target from $3.75 to $4 while maintaining a Neutral rating [1][3] Company Performance - GoodRx reported strong performance in its third quarter of 2025, particularly through its pharmaceutical manufacturer solutions [3] - The company is actively working on expanding accessibility and affordability programs and is in discussions regarding participation in the TrumpRx initiative [2] Marketing and Brand Initiatives - A new brand campaign has been launched by GoodRx to enhance awareness of its consumer products and services, including new subscription services targeting hair loss and weight loss treatments [4] Industry Challenges - The industry faces ongoing challenges, including uncertainties surrounding the Affordable Care Act marketplace subsidies and Medicaid support [3] - Potential regulatory changes and platform launches from Washington could lead to volatility for GoodRx [5] - Consumer affordability challenges are expected to remain a significant concern for investors [5] Company Overview - GoodRx is recognized for its digital healthcare platform that connects various stakeholders, including consumers, healthcare professionals, payers, PBMs, pharmaceutical manufacturers, and retail pharmacies, to improve medication affordability and accessibility [6]

Core Insights - WELL Health Technologies Corp. reported strong interim consolidated financial results for the quarter ended September 30, 2025, indicating positive growth and performance [1] Financial Performance - The company experienced significant growth in its financial metrics, reflecting a successful quarter driven by strategic initiatives [1] - Specific financial figures and percentage changes were not detailed in the provided text, but the overall performance was characterized as excellent [1] Strategic Focus - WELL Health Technologies is focused on leveraging technology to enhance health outcomes for healthcare practitioners and patients globally, emphasizing its commitment to digital healthcare solutions [1]

Core Insights - WELL Health Technologies Corp. has announced that its majority-owned subsidiary WELLSTAR Technologies Corp. has entered into agreements to complete a Series B funding round [1] Company Overview - WELL Health Technologies Corp. is a digital healthcare company focused on improving health outcomes by leveraging technology to empower healthcare practitioners and their patients globally [1]

Core Insights - Hims & Hers Health, Inc. is enhancing its healthcare services through artificial intelligence, data infrastructure, and personalized treatment pathways, aiming to create a next-generation healthcare experience [1][7] - The appointment of Mo Elshenawy as CTO is a significant move towards AI-driven automation and intelligent diagnostics, aligning with the company's vision for global personalized care [2] - Recent product launches, including personalized oral testosterone and menopause care, utilize data-driven models to tailor treatments to individual patient needs [3] Company Developments - Hims & Hers has initiated an $870 million convertible notes offering to boost investments in data infrastructure and personalized treatment technologies [2] - The company has reported a 104.1% increase in share price year-to-date, outperforming the industry growth of 28.2% [6] Financial Performance - Hims & Hers has a forward 12-month price-to-sales ratio of 4.1X, which is lower than the industry average of 5.9X but higher than its three-year median of 2.5X [9] - The Zacks Consensus Estimate for Hims & Hers' earnings per share in 2025 indicates a 118.5% improvement from 2024 [9]

Core Viewpoint - Healthcare and telemedicine stocks, particularly Hims & Hers Health, have been significant market winners due to increasing demand for virtual care and wellness solutions, but recent events have raised concerns about the company's future performance [1][2]. Company Overview - Hims & Hers Health is a prominent player in digital healthcare, connecting users to licensed medical professionals through its telehealth platform, offering treatments in various areas including mental health and sexual wellness [3]. - The company has experienced substantial growth, with its stock surging 109% year-to-date, driven by internal momentum and product expansion [4]. Recent Developments - CEO Andrew Dudum's sale of approximately $11 million in stock has led to a more than 10% drop in shares, raising concerns about the company's stability amid regulatory issues and pricing pressures on GLP-1 generics [2]. - Hims & Hers has introduced a Menopause and Perimenopause specialty within its "Hers" division, aiming to drive revenue past $1 billion by 2026, which could account for over a third of total sales [6]. Financial Metrics - The company's current valuation appears challenging, with a price-to-book (P/B) ratio of 22, significantly higher than the sector median of 3, indicating the stock is expensive [5]. - The EV/EBITDA ratio stands at 76, well above the sector median of 14, suggesting that Hims & Hers is trading at a substantial premium [5].